Transcatheter valve replacement curbs tricuspid regurgitation in many

Reuters Health - 26/11/2020 - Patients at high surgical risk with severe, symptomatic functional tricuspid regurgitation (TR) treated with a first-generation transcatheter tricuspid-valve implantation (TTVI) system show significant clinical improvement, according to a multicenter report of compassionate use. "Further refinement of the implantation algorithm may reduce malpositioning of the device, leading to better TR reduction," Dr. Rebecca T. Hahn of New York-Presbyterian Hospital, in New York City, told Reuters Health by email. "Device iteration towards reduced invasiveness and improved patient-selection criteria are needed to improve procedural safety, along with larger prospective studies to assess the impact on long-term clinical outcomes." Isolated TR surgery is associated with high in-hospital mortality, Dr. Hahn and her colleagues note in JACC: Cardiovascular Interventions. To evaluate the feasibility and safety of TTVI in patients at "extreme" surgical ris...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 26 November, 20204 December, 2020